{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:24:46Z","timestamp":1777962286704,"version":"3.51.4"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Multiple sclerosis (MS) is an autoimmune disease targeting the central nervous system, characterized by an unpredictable disease course and a wide range of symptoms. Emotional and cognitive deficits are now recognized as primary disease manifestations and not simply the consequence of living with a chronic condition, raising questions regarding the efficacy of current therapeutics for these specific symptoms. Mechanisms underlying psychiatric sequelae in MS are believed to be similar to those underlying pathogenesis, that is mediated by cytokines and other inflammatory mediators. To gain insight into the pathogenesis of MS depression, we performed behavioral assays in the murine experimental autoimmune encephalomyelitis (EAE) MS model, in the presence or absence of immunomodulation using the drug FTY720, an analogue of the lipid signaling molecule sphingosine-1-phosphate (S1P). Specifically, mice were challenged with the elevated plus maze (EPM) test, a validated experimental paradigm for rodent-specific anxiety-like behavior. FTY720 treatment failed to ameliorate anxiety-like symptoms, irrespective of dosage. On the other hand, it was effective in reducing inflammatory infiltration, microglial reactivity and levels of pro-inflammatory molecules in the hippocampus, confirming the anti-inflammatory capacity of treatment. To explore the absence of FTY720 effect on behavior, we confirmed expression of S1P receptors (S1PR) S1PR1, S1PR3 and S1PR5 in the hippocampus and mapped the dynamics of these receptors in response to drug treatment alone, or in combination with EAE induction. We identified a complex pattern of responses, differing between (1) receptors, (2) dosage and (3) hippocampal sub-field. FTY720 treatment in the absence of EAE resulted in overall downregulation of S1PR1 and S1PR3, while S1PR5 exhibited a dose-dependent upregulation. EAE induction alone resulted in overall downregulation of all three receptors. On the other hand, combined FTY720 and EAE showed generally no effect on S1PR1 and S1PR3 expression except for the fimbrium region, but strong upregulation of S1PR5 over the range of doses examined. These data illustrate a hitherto undescribed complexity of S1PR response to FTY720 in the hippocampus, independent of drug effect on effector immune cells, but simultaneously emphasize the need to explore novel treatment strategies to specifically address mood disorders in MS.<\/jats:p>","DOI":"10.3389\/fimmu.2021.639650","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T08:53:44Z","timestamp":1623315224000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Immunomodulation Eliminates Inflammation in the Hippocampus in Experimental Autoimmune Encephalomyelitis, but Does Not Ameliorate Anxiety-Like Behavior"],"prefix":"10.3389","volume":"12","author":[{"given":"Pece","family":"Kocovski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuzhat","family":"Tabassum-Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Marinis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phuc T.","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew W.","family":"Hale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline M.","family":"Orian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple Sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2015.49","article-title":"Multiple Sclerosis-a Quiet Revolution","volume":"11","author":"Ransohoff","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.139","article-title":"The Link Between Multiple Sclerosis and Depression","volume":"10","author":"Feinstein","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.11.067","article-title":"Prevalence of Depression and Anxiety in Multiple Sclerosis: A Systematic Review and Meta-Analysis","volume":"372","author":"Boeschoten","year":"2017","journal-title":"J Neurol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.11.003","article-title":"The Prevalence of Anxiety and Associated Factors in Persons With Multiple Sclerosis","volume":"19","author":"Pham","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"B6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12888-016-0931-5","article-title":"The Assessment of Depression in People With Multiple Sclerosis: A Systematic Review of Psychometric Validation Studies","volume":"16","author":"Hind","year":"2016","journal-title":"BMC Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11910-019-0992-1","article-title":"Depression and Suicidality in Multiple Sclerosis: Red Flags, Management Strategies, and Ethical Considerations","volume":"19","author":"Kalb","year":"2019","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004411","article-title":"Neuroinflammation Drives Anxiety and Depression in Relapsing-Remitting Multiple Sclerosis","volume":"89","author":"Rossi","year":"2017","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tics.2013.03.005","article-title":"Long-Axis Specialization of the Human Hippocampus","volume":"17","author":"Poppenk","year":"2013","journal-title":"Trends Cognit Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.biopsych.2015.11.022","article-title":"Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis","volume":"80","author":"Colasanti","year":"2016","journal-title":"Biol Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30309-0","article-title":"The Hippocampus in Multiple Sclerosis","volume":"17","author":"Rocca","year":"2018","journal-title":"Lancet Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510374893","article-title":"Hippocampal Atrophy in Relapsing-Remitting and Primary Progressive MS: A Comparative Study","volume":"16","author":"Anderson","year":"2010","journal-title":"Mult Scler"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511403530","article-title":"Decreased Hippocampal Volume, Indirectly Measured, is Associated With Depressive Symptoms and Consolidation Deficits in Multiple Sclerosis","volume":"17","author":"Kiy","year":"2011","journal-title":"Mult Scler"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.mri.2013.12.012","article-title":"Hippocampal Volume is Related to Cognitive Decline and Fornicial Diffusion Measures in Multiple Sclerosis","volume":"32","author":"Koenig","year":"2014","journal-title":"Magn Reson Imaging"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7763-y","article-title":"Cognitive Impairment and Memory Disorders in Relapsing-Remitting Multiple Sclerosis: The Role of White Matter, Gray Matter and Hippocampus","volume":"262","author":"Sacco","year":"2015","journal-title":"J Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.23125","article-title":"Structural MRI Correlates of Cognitive Impairment in Patients With Multiple Sclerosis: A Multicenter Study","volume":"37","author":"Preziosa","year":"2016","journal-title":"Hum Brain Mapp"},{"key":"B17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/WNR.0000000000000920","article-title":"Multiple Pathological Mechanisms Contribute to Hippocampal Damage in the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis","volume":"29","author":"Kyran","year":"2018","journal-title":"Neuroreport"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00451.x","article-title":"FTY720 (Fingolimod) in Multiple Sclerosis: Therapeutic Effects in the Immune and the Central Nervous System","volume":"158","author":"Brinkmann","year":"2009","journal-title":"Br J Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): Discovery and Development of an Oral Drug to Treat Multiple Sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat Rev Drug Discovery"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511411061","article-title":"Oral Fingolimod (FTY720) in Relapsing Multiple Sclerosis: Impact on Health-Related Quality of Life in a Phase II Study","volume":"17","author":"Montalban","year":"2011","journal-title":"Mult Scler"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pnpbp.2019.03.001","article-title":"Novel Insights Into the Mechanisms Underlying Depression-Associated Experimental Autoimmune Encephalomyelitis","volume":"93","author":"Duarte-Silva","year":"2019","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31820d5ec1","article-title":"Sphingosine 1-Phosphate (S1P): Physiology and the Effects of S1P Receptor Modulation","volume":"76","author":"Hla","year":"2011","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0264-y","article-title":"Fingolimod: A Review of its Use in Relapsing-Remitting Multiple Sclerosis","volume":"74","author":"Sanford","year":"2014","journal-title":"Drugs"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.02.007","article-title":"Multiple Sclerosis in the Real World: A Systematic Review of Fingolimod as a Case Study","volume":"16","author":"Ziemssen","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2018.03.018","article-title":"Real-World Persistence With Fingolimod for the Treatment of Multiple Sclerosis: A Systematic Review and Meta-Analysis","volume":"388","author":"Kantor","year":"2018","journal-title":"J Neurol Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1014154108","article-title":"FTY720 (Fingolimod) Efficacy in an Animal Model of Multiple Sclerosis Requires Astrocyte Sphingosine 1-Phosphate Receptor 1 (S1P1) Modulation","volume":"108","author":"Choi","year":"2011","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2016.00258","article-title":"Ablation of Sphingosine 1-Phosphate Receptor Subtype 3 Impairs Hippocampal Neuron Excitability In Vitro and Spatial Working Memory In Vivo","volume":"10","author":"Weth-Malsch","year":"2016","journal-title":"Front Cell Neurosci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2007.44","article-title":"The Use of the Elevated Plus Maze as an Assay of Anxiety-Related Behavior in Rodents","volume":"2","author":"Walf","year":"2007","journal-title":"Nat Protoc"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0270(85)90031-7","article-title":"Validation of Open: Closed Arm Entries in an Elevated Plus-Maze as a Measure of Anxiety in the Rat","volume":"14","author":"Pellow","year":"1985","journal-title":"J Neurosci Methods"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(00)00392-0","article-title":"Estrous Cycle and Sex Differences in Performance on Anxiety Tasks Coincide With Increases in Hippocampal Progesterone and 3\u03b1, 5\u03b1-Thp","volume":"67","author":"Frye","year":"2000","journal-title":"Pharmacol Biochem Behav"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2013.155","article-title":"Object Recognition Test in Mice","volume":"8","author":"Leger","year":"2013","journal-title":"Nat Protoc"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/0023677218756156","article-title":"Differential Anxiety-Like Responses in NOD\/ShiLtJ and C57BL\/6J Mice Following Experimental Autoimmune Encephalomyelitis Induction and Oral Gavage","volume":"52","author":"Kocovski","year":"2018","journal-title":"Lab Anim"},{"key":"B33","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3390\/jcm8020162","article-title":"Platelet Depletion is Effective in Ameliorating Anxiety-Like Behavior and Reducing the Pro-Inflammatory Environment in the Hippocampus in Murine Experimental Autoimmune Encephalomyelitis","volume":"8","author":"Kocovski","year":"2019","journal-title":"J Clin Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.expneurol.2012.07.010","article-title":"TNF-Alpha-Mediated Anxiety in a Mouse Model of Multiple Sclerosis","volume":"237","author":"Haji","year":"2012","journal-title":"Exp Neurol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2013.07.003","article-title":"Altered Cognitive-Emotional Behavior in Early Experimental Autoimmune Encephalitis\u2013Cytokine and Hormonal Correlates","volume":"33","author":"Acharjee","year":"2013","journal-title":"Brain Behav Immun"},{"key":"B36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jneuroim.2010.10.006","article-title":"Experimental Autoimmune Encephalomyelitis (EAE) IN C57Bl\/6 Mice is Not Associated With Astrogliosis","volume":"232","author":"Pham","year":"2011","journal-title":"J Neuroimmunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jneumeth.2014.08.006","article-title":"A Computational Model for Exploratory Activity of Rats With Different Anxiety Levels in Elevated Plus-Maze","volume":"236","author":"Costa","year":"2014","journal-title":"J Neurosci Method"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2014.987344","article-title":"Deletion of IL-4Ralpha in the BALB\/c Mouse is Associated With Altered Lesion Topography and Susceptibility to Experimental Autoimmune Encephalomyelitis","volume":"48","author":"Orian","year":"2015","journal-title":"Autoimmunity"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2015.06.052","article-title":"Anxiogenic Drug Administration and Elevated Plus-Maze Exposure in Rats Activate Populations of Relaxin-3 Neurons in the Nucleus Incertus and Serotonergic Neurons in the Dorsal Raphe Nucleus","volume":"303","author":"Lawther","year":"2015","journal-title":"Neuroscience"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nly032","article-title":"Platelets Drive Inflammation and Target Gray Matter and the Retina in Autoimmune-Mediated Encephalomyelitis","volume":"77","author":"D\u2019souza","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.12.010","article-title":"The Astrocytic Response in Early Experimental Autoimmune Encephalomyelitis Occurs Across Both the Grey and White Matter Compartments","volume":"208","author":"Pham","year":"2009","journal-title":"J Neuroimmunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2003.08.018","article-title":"Early Glial Responses in Murine Models of Multiple Sclerosis","volume":"45","author":"Ayers","year":"2004","journal-title":"Neurochem Int"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.20127","article-title":"Structural and Functional Characteristics of S1P Receptors","volume":"92","author":"Sanchez","year":"2004","journal-title":"J Cell Biochem"},{"key":"B44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1124\/mol.105.020552","article-title":"Sphingosine and its Analog, the Immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, Interact With the CB1 Cannabinoid Receptor","volume":"70","author":"Paugh","year":"2006","journal-title":"Mol Pharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/10409238.2010.522975","article-title":"Roles for Lysophospholipid S1P Receptors in Multiple Sclerosis","volume":"46","author":"Noguchi","year":"2011","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R046300","article-title":"An Update on the Biology of Sphingosine 1-Phosphate Receptors","volume":"55","author":"Blaho","year":"2014","journal-title":"J Lipid Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e0170825","DOI":"10.1371\/journal.pone.0170825","article-title":"Prophylactic Versus Therapeutic Fingolimod: Restoration of Presynaptic Defects in Mice Suffering From Experimental Autoimmune Encephalomyelitis","volume":"12","author":"Bonfiglio","year":"2017","journal-title":"PloS One"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011437","article-title":"The Immunosuppressant Drug FTY720 Inhibits Cytosolic Phospholipase A2 Independently of sphingosine-1-phosphate Receptors","volume":"109","author":"Payne","year":"2007","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M805186200","article-title":"FTY720 Inhibits Ceramide Synthases and Up-Regulates Dihydrosphingosine 1-Phosphate Formation in Human Lung Endothelial Cells","volume":"284","author":"Berdyshev","year":"2009","journal-title":"J Biol Chem"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M807438200","article-title":"Ceramide Synthesis is Modulated by the Sphingosine Analog FTY720 Via a Mixture of Uncompetitive and Noncompetitive Inhibition in an Acyl-CoA Chain Length-Dependent Manner","volume":"284","author":"Lahiri","year":"2009","journal-title":"J Biol Chem"},{"key":"B51","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejps.2016.09.016","article-title":"Fingolimod Enhances Myelin Repair of Hippocampus in Pentylenetetrazol-Induced Kindling Model","volume":"96","author":"Gol","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bbalip.2012.07.015","article-title":"And Chun, J. (2013). Lysophospholipids and Their Receptors in the Central Nervous System","volume":"1831","author":"Choi","year":"1831","journal-title":"Biochim Biophys Acta"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2008.06.031","article-title":"Central Nervous System-Directed Effects of FTY720 (Fingolimod)","volume":"274","author":"Miron","year":"2008","journal-title":"J Neurol Sci"},{"key":"B54","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrm1103","article-title":"Sphingosine-1-phosphate: An Enigmatic Signalling Lipid","volume":"4","author":"Spiegel","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12883-014-0220-1","article-title":"Impact of a Switch to Fingolimod Versus Staying on Glatiramer Acetate or Beta Interferons on Patient- and Physician-Reported Outcomes in Relapsing Multiple Sclerosis: Post Hoc Analyses of the EPOC Trial","volume":"14","author":"Calkwood","year":"2014","journal-title":"BMC Neurol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e00135","DOI":"10.1002\/prp2.135","article-title":"Antidepressant Activity of Fingolimod in Mice","volume":"3","author":"Di Nuzzo","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-019-0471-8","article-title":"Effects of Immunomodulatory Drugs on Depressive Symptoms: A Mega-Analysis of Randomized, Placebo-Controlled Clinical Trials in Inflammatory Disorders","volume":"25","author":"Wittenberg","year":"2019","journal-title":"Mol Psychiatry"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2017.03.016","article-title":"The Anti-Inflammatory Mechanism of Antidepressants - SSRIs, Snris","volume":"80","author":"Galecki","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.639650\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T08:53:48Z","timestamp":1623315228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.639650\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2021.639650"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.639650","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"article-number":"639650"}}